Open AccessSafety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study
Author(s) -
Valéria Basso,
David Orry,
J. Fraisse,
Julie Vincent,
Audrey Hennequin,
Leila Bengrine,
François Ghiringhelli
Publication year - 2019
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v11.i8.634
Subject(s) - medicine , docetaxel , regimen , oxaliplatin , perioperative , trastuzumab , surgery , chemotherapy , retrospective cohort study , gastroenterology , cancer , oncology , breast cancer , colorectal cancer
Triplet chemotherapy, with docetaxel-5FU-oxaliplatin FLOT regimen recently became the standard perioperative treatment for localized gastric cancer (GC). An adapted regimen called TeFOX was recently tested in metastatic setting and gave promising results.